Lin Wei - 17 Mar 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Medical Officer
Issuer ticker: RVMD
Reported as of: 17 Mar 2026
Net transaction value: -$206,223
SEC form: 4
Accepted by SEC: 19 Mar 2026, 18:57:49 UTC
Prior SEC filing: 03 Mar 2026
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Wei Lin

Key filing fact

Lin Wei filed Form 4 for Revolution Medicines, Inc. (RVMD) on 19 Mar 2026.

Key facts

This page summarizes Lin Wei's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Mar 2026, 18:57.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$206,223.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001872772 Primary reporting owner

Wei Lin

Relationship: Chief Medical Officer
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Wei Lin
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $206,223
Shares: -2,073
Change %: -2%
Price: $99.48
Shares after: 101,366
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.

Footnote F2

Includes 62,050 RSUs.